Last reviewed · How we verify
Oseltamivir IV
Oseltamivir is a neuraminidase inhibitor that blocks the release of influenza virus particles from infected cells, reducing viral spread.
Oseltamivir is a neuraminidase inhibitor that blocks the release of influenza virus particles from infected cells, reducing viral spread. Used for Treatment of acute influenza infection in hospitalized patients, Prophylaxis of influenza in high-risk patients.
At a glance
| Generic name | Oseltamivir IV |
|---|---|
| Also known as | TAMIFLU® |
| Sponsor | Hoffmann-La Roche |
| Drug class | Neuraminidase inhibitor |
| Target | Influenza neuraminidase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Oseltamivir phosphate is converted to its active form and inhibits influenza neuraminidase, an enzyme on the viral surface required for budding and release of new viral particles from host cells. By blocking neuraminidase activity, the drug prevents viral dissemination and reduces the duration and severity of influenza infection. The IV formulation provides direct systemic delivery for patients unable to take oral medication.
Approved indications
- Treatment of acute influenza infection in hospitalized patients
- Prophylaxis of influenza in high-risk patients
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Headache
- Neuropsychiatric events
Key clinical trials
- Dexmedetomidine-Enhanced PCIA After Lobectomy in Nicotine-Dependent Patients (PHASE4)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- Intravenous N-acetylcysteine and Oseltamivir Versus Oseltamivir in Adults Hospitalized With Influenza and Pneumonia (PHASE3)
- Study of Efficacy and Safety of IV VIS410 Plus Oseltamivir Versus Oseltamivir in Hospitalized Adults With Influenza A (PHASE2)
- Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized) (PHASE3)
- Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated Influenza (PHASE3)
- Study to Evaluate the Efficacy and Safety of Danirixin Co-administered With Oseltamivir in the Treatment of Adults Hospitalized With Influenza (PHASE2)
- Isotretinoin in Treatment of COVID-19 (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |